ALPHA LIPOIC ACID

Possibly Marketed Outside US

First approved in 2001

Details

Stereochemistry	RACEMIC
Molecular Formula	C8H14O2S2
Molecular Weight	206.326
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCCCC1CCSS1

InChI

InChIKey=AGBQKNBQESQNJD-UHFFFAOYSA-N

InChI=1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)

HIDE SMILES / InChI

Molecular Formula	C8H14O2S2
Molecular Weight	206.326
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19664690 | https://www.ncbi.nlm.nih.gov/pubmed/25104975

Thioctic acid also known as alpha-lipoic acid is a dietary supplement, which is a common ingredient in OTC (over-the-counter) multivitamin formulas and anti-aging supplements. Thioctic acid exists in both R- and S-enantiomeric forms, however, only R-form is essential as a cofactor in biological systems (the acid is coupled via an amide linkage to a lysine of several multienzyme complexes, such as the pyruvate dehydrogenase complex, the alpha-ketoglutarate dehydrogenase complex, the glycine cleavage system and the branched-chain oxo acid dehydrogenase complex). Most commercially available thioctic acid supplements are a mixture of both R and S enantiomers or R-form alone. Several studies have shown that the acid has beneficial effect on diabetes complications, cancer, glaucome, liver disease, etc. The mechanisms of thioctic acid is related to its antioxidant properties, metal chelator properties, however, those mechanisms need futher confirmation.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: http://www.altmedrev.com/publications/11/3/232.pdf	Palliative	Phase IV 63	Unknown Approved Use Unknown
Nonalcoholic steatohepatitis 9 Sources: https://www.clinicaltrials.gov/ct2/show/NCT01406704	Primary	Phase IV 63	Unknown Approved Use Unknown
Subchorionic hematoma 3 Sources: https://www.clinicaltrials.gov/ct2/show/NCT02601898	Primary	Phase IV 63	Unknown Approved Use Unknown
Stress (tako-tsubo) cardiomyopathy 3 Sources: https://www.clinicaltrials.gov/ct2/show/NCT01524861	Primary	Phase IV 63	Unknown Approved Use Unknown
Women infertility 3 Sources: https://www.clinicaltrials.gov/ct2/show/NCT03023514	Primary	Phase IV 63	Unknown Approved Use Unknown
Carpal tunnel syndrome 3 Sources: https://www.clinicaltrials.gov/ct2/show/NCT01895621	Palliative	Phase IV 63	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
7.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30241687/	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		THIOCTIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
5.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30241687/	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		THIOCTIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30241687/	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		THIOCTIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
600 mg 1 times / day multiple, oral Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15120701/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/15120701/	Disc. AE: Gastrointestinal disturbance... AEs leading to discontinuation/dose reduction: Gastrointestinal disturbance (8.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/15120701/
600 mg 3 times / day multiple, oral Recommended Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21187189/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21187189/	Other AEs: Itching... Other AEs: Itching (0.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/21187189/
600 mg 3 times / day multiple, oral Recommended Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27276401/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27276401/	Disc. AE: Skin eruption... AEs leading to discontinuation/dose reduction: Skin eruption (10%) Sources: https://pubmed.ncbi.nlm.nih.gov/27276401/

AEs

AE	Significance	Dose	Population
Gastrointestinal disturbance	8.2% Disc. AE	600 mg 1 times / day multiple, oral Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15120701/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/15120701/
Itching	0.8%	600 mg 3 times / day multiple, oral Recommended Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21187189/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21187189/
Skin eruption	10% Disc. AE	600 mg 3 times / day multiple, oral Recommended Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27276401/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27276401/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2E1 1060 CYP1A2 2153 CYP2A6 879 CYP2C19 2057 BSEP 550 P-gp 1741 OATP1B3 961 OATP1B1 1079 CYP19A1 429 BCRP 910 CYP3A 227	P-gp 2052	GLUT1 14 GLUT4 5

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTM0MzQyIn19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTM0MzQyIn19	no [IC50 >10 uM]
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >1000 uM]
BCRP 985	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/864#section=BioAssay-Results Page: 69.0	no
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/864#section=BioAssay-Results Page: 346.0	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/864#section=BioAssay-Results Page: 71.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	yes [Inhibition 10 uM]
CYP3A 317	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/18838505/	yes
GLUT1 20	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/23984871/	yes
GLUT4 20	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/23984871/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/864#section=BioAssay-Results Page: 448 \| 449	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTM0MzQyIn19

PubMed

Title	Date	PubMed
Potent upregulation of glutathione and NAD(P)H:quinone oxidoreductase 1 by alpha-lipoic acid in human neuroblastoma SH-SY5Y cells: protection against neurotoxicant-elicited cytotoxicity.	2008-05	17940886
Therapeutic efficacy of DL-alpha-lipoic acid on cyclosporine A induced renal alterations.	2007-10-01	17619014
Adjunctive care with nutritional, herbal, and homeopathic complementary and alternative medicine modalities in stroke treatment and rehabilitation.	2007-08-19	17698456
CoCl2 induces protective events via the p38-MAPK signalling pathway and ANP in the perfused amphibian heart.	2007-07	17575032
Beneficial effect of DL-alpha-lipoic acid on cyclosporine A induced hyperlipidemic nephropathy in rats.	2007-07	17225189
Unusual fluorescence enhancement of a novel carbazolyldiacetylene bound to gold nanoparticles.	2007-06-05	17488044
Effect of DL-alpha-lipoic acid on cyclophosphamide induced lysosomal changes in oxidative cardiotoxicity.	2007-05-01	17418239
Efficacy of DL-alpha-lipoic acid on methanol induced free radical changes, protein oxidative damages and hsp70 expression in folate deficient rat nervous tissue.	2007-05-01	17399694
Monolayer-protected gold nanoparticles by the self-assembly of micellar poly(ethylene oxide)-b-poly(epsilon-caprolactone) block copolymer.	2007-02-13	17279704
Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice.	2007-02	17255331
Acrolein, a toxicant in cigarette smoke, causes oxidative damage and mitochondrial dysfunction in RPE cells: protection by (R)-alpha-lipoic acid.	2007-01	17197552
Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT.	2007-01	17044076
Diabetic painful neuropathy: current and future treatment options.	2007	17352515
Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation.	2006-12	16990509
Interfacial pH and surface pKa of a thioctic acid self-assembled monolayer.	2006-11-07	17043716
Protective role of eicosapentaenoate-lipoate (EPA-LA) derivative in combating oxidative hepatocellular injury in hypercholesterolemic atherogenesis.	2006-11	16458314
Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes.	2006-10-31	17079870
Application of N-PLS calibration to the simultaneous determination of Cu(2+), Cd(2+) and Pb(2+) using peptide modified electrochemical sensors.	2006-09	17047806
Insight into the role of DL-alpha-lipoic acid against cyclophosphamide induced alterations in calcium sensitivity of cardiac myofilaments.	2006-09	16625422
Protective effect of DL-alpha-lipoic acid on cyclophosphamide induced hyperlipidemic cardiomyopathy.	2006-08-14	16814280
RS-alpha-lipoic acid protects cholinergic cells against sodium nitroprusside and amyloid-beta neurotoxicity through restoration of acetyl-CoA level.	2006-08	16787407
Antioxidants reduce cone cell death in a model of retinitis pigmentosa.	2006-07-25	16849425
Contact dermatitis to alpha-lipoic acid in an anti-wrinkle cream.	2006-07	16842558
Biofunctional ZnO nanorod arrays grown on flexible substrates.	2006-06-20	16768511
Oxidative stress-mediated macromolecular damage and dwindle in antioxidant status in aged rat brain regions: role of L-carnitine and DL-alpha-lipoic acid.	2006-06	16480704
Salubrious effects of lipoic acid against adriamycin-induced clastogenesis and apoptosis in Wistar rat bone marrow cells.	2006-05-15	16580770
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.	2006-05	16702388
Oxidative stress and DNA single strand breaks in skeletal muscle of aged rats: role of carnitine and lipoicacid.	2006-04	16802114
Carnitine and lipoic acid alleviates protein oxidation in heart mitochondria during aging process.	2006-04	16802113
Modulatory role of lipoic acid on adriamycin-induced testicular injury.	2006-03-25	16434030
MafA expression and insulin promoter activity are induced by nicotinamide and related compounds in INS-1 pancreatic beta-cells.	2006-03	16505238
[Oxaliplatin neurotoxicity].	2006-02-01	16491518
Protective effect of lipoic acid on micronuclei induction by cyclophosphamide.	2006-02	16088343
Protective efficacy of alpha-lipoic acid on acetylcholinesterase activity in aged rat brain regions.	2006	16706642
Decrease in NADPH-cytochrome P450 reductase activity of the human heart, Liver and lungs in the presence of alpha-lipoic acid.	2006	16391466
Combined efficacies of DL-alpha-lipoic acid and meso 2,3 dimercaptosuccinic acid against arsenic induced toxicity in antioxidant systems of rats.	2005-12-30	15998567
dl-alpha-lipoic acid ameliorates cyclophosphamide induced cardiac mitochondrial injury.	2005-11-05	16085348
(R)-alpha-lipoic acid protects retinal pigment epithelial cells from oxidative damage.	2005-11	16249512
Plasmodium falciparum possesses organelle-specific alpha-keto acid dehydrogenase complexes and lipoylation pathways.	2005-11	16246025
Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity.	2005-11	16236146
Cytoprotective role of DL-alpha-lipoic acid in cyclophosphamide induced myocardial toxicity.	2005-08	16132683
Brain regional responses in antioxidant system to alpha-lipoic acid in arsenic intoxicated rat.	2005-05-15	15804455
Evidence for a non-antioxidant, dose-dependent role of alpha -lipoic acid in caspase-3 and ERK2 activation in endothelial cells.	2005-05	15909127
Attenuation of serum lipid abnormalities and cardiac oxidative stress by eicosapentaenoate-lipoate (EPA-LA) derivative in experimental hypercholesterolemia.	2005-05	15820496
Oxidative stress on mitochondrial antioxidant defense system in the aging process: role of DL-alpha-lipoic acid and L-carnitine.	2005-05	15820492
The protective role of DL-alpha-lipoic acid in biogenic amines catabolism triggered by Abeta amyloid vaccination in mice.	2005-04-30	15811602
Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice.	2005-04-29	15862133
Mitigation of oxidative stress in cyclophosphamide-challenged hepatic tissue by DL-alpha-lipoic acid.	2005-04	16010986
Arsenic intoxication-induced reduction of glutathione level and of the activity of related enzymes in rat brain regions: reversal by DL-alpha-lipoic acid.	2005-03	15798887
The protective role of DL-alpha-lipoic acid in the oxidative vulnerability triggered by Abeta-amyloid vaccination in mice.	2005-02	15792351

Patents

Sample Use Guides

In Vivo Use Guide

Recommended oral therapeutic dosages of alpha-lipoic acid range from 600-1800 mg daily.

Route of Administration: Oral

In Vitro Use Guide

Supplementation of Human Umbilical Vein Endothelial Cells with 100, 200, or 500 uM thioctic acid after inoculation with R. rickettsii restored the intracellular levels of thiols and glutathione peroxidase and reduced the intracellular peroxide levels in infected cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:34:08 GMT 2025` Edited by `admin` on `Mon Mar 31 17:34:08 GMT 2025`
Record UNII	73Y7P0K73Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

.ALPHA.-LIPOIC ACID

Preferred Name

English

ALPHA LIPOIC ACID

Official Name

English

THIOCTIC ACID

Preferred Name

English

DL-6,8-THIOCTIC ACID

Common Name

English

ALPHA LIPOIC ACID [VANDF]

Common Name

English

NSC-90788

Code

English

BILETAN

Brand Name

English

ALPHA-LIPOIC ACID

Common Name

English

THIOCTIC ACID DL-FORM [MI]

Common Name

English

THIOCTIC ACID, (±)-

Common Name

English

NSC-628502

Code

English

ACIDUM THIOCTICUM

Common Name

English

6,8-THIOCTIC ACID

Common Name

English

THIOCACID

Brand Name

English

Thioctic acid [WHO-DD]

Common Name

English

1,2-DITHIOLANE-3-PENTANOIC ACID

Systematic Name

English

ALPHA-LIPOIC ACID [VANDF]

Common Name

English

THIOCTIC ACID [MART.]

Common Name

English

THIOCTIC ACID [JAN]

Common Name

English

A-LIPOICUM ACIDUM

Common Name

English

TIOCTIC ACID

Common Name

English

LIPOIC ACID, DL-

Common Name

English

THIOCTIC ACID [HSDB]

Common Name

English

.DELTA.-(3-(1,2-DITHIACYCLOPENTYL))PENTANOIC ACID

Common Name

English

ALPHA LIPOIC ACID [USP IMPURITY]

Common Name

English

THIOCTIC ACID [MI]

Common Name

English

THIOCTIC ACID [EP MONOGRAPH]

Common Name

English

5-(3-(1,2-DITHIOLANYL))PENTANOIC ACID

Common Name

English

A-LIPOICUM ACIDUM [HPUS]

Common Name

English

ALPHA LIPOIC ACID [USP-RS]

Common Name

English

.ALPHA.-LIPOIC ACID, (±)-

Common Name

English

THIOCTATE

Common Name

English

5-(1,2-DITHIOLAN-3-YL)VALERIC ACID

Systematic Name

English

1,2-DITHIOLANE-3-VALERIC ACID

Systematic Name

English

5-((3RS)-1,2-DITHIOLAN-3-YL)PENTANOIC ACID

Systematic Name

English

THIOCTAN

Brand Name

English

Classification Tree Code System Code

WHO-VATC

QA16AX01